Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr. Barocas on Adjuvant Sunitinib in Renal Cell Carcinoma

January 9th 2020

Daniel A. Barocas, MD, MPH, FACS, discusses adjuvant TKI therapy in patients with renal cell carcinoma at high risk of recurrence following cytoreductive nephrectomy.

Dr. McDermott on the Use of PD-1 Inhibitor Combos in mRCC

January 8th 2020

David F. McDermott, MD, discusses the use of PD-1 inhibitors in combination with VEGF inhibitors and CTLA-4 inhibitors in metastatic renal cell carcinoma.

Single-Agent and Combo Approvals Lead to Personalized Approach in RCC

January 6th 2020

Ajjai Shivaram Alva, MBBS, highlights ongoing advances made in the treatment of patients with metastatic renal cell carcinoma.

Dr. Alva on the Toxicity Profiles of TKIs in RCC

January 6th 2020

Ajjai Shivaram Alva, MBBS, discusses class-specific toxicities of TKIs in renal cell carcinoma.

Dr. Vaishampayan on the Role of Cytoreductive Nephrectomy in mRCC

January 3rd 2020

Ulka Vaishampayan, MD, professor of oncology at Wayne State University, and the chief of the Solid Tumor Program at Barbara Ann Karmanos Cancer Institute, discusses the current role of cytoreductive nephrectomy in metastatic renal cell carcinoma.

Predictive Biomarkers Needed for Immunotherapy Combo Choice in Frontline RCC

January 2nd 2020

Ulka Vaishampayan, MD, discusses the role of frontline immunotherapy and patient selection in metastatic renal cell carcinoma. 

Assessing Long-Anticipated Treatment Advances in Metastatic Urothelial Cancer

January 2nd 2020

Nancy B. Davis, MD, discusses the excitement with targeted therapies as well as anticipated combination strategies under investigation in advanced urothelial cancer.

Experts Provide Insight on the Biggest Advances in Oncology in 2019

January 1st 2020

OncLive interviewed experts at the State of the Science Summits™ in December 2019 on what the biggest advances in oncology were in 2019.

Frontline Pembrolizumab/Axitinib Approved in Japan for Advanced RCC

December 21st 2019

Japan’s Pharmaceuticals and Medical Devices Agency has approved the combination of pembrolizumab and axitinib for the first-line treatment of patients with radically unresectable or metastatic renal cell carcinoma.

FDA Grants Priority Review to UGN-101 for Urothelial Cancer

December 19th 2019

The FDA has granted a priority review designation to a new drug application for UGN-101 for the treatment of patients with low-grade, upper tract urothelial cancer.

FDA Approves Enfortumab Vedotin for Urothelial Cancer

December 19th 2019

The FDA has approved enfortumab vedotin-ejfv for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have received prior treatment with a PD-1/PD-L1 inhibitor and platinum-containing chemotherapy.

Frontline Immunotherapy Approvals Raise Treatment Selection Challenge in RCC

December 16th 2019

Robert J. Motzer, MD, discusses the current frontline treatment landscape of metastatic renal cell carcinoma amongst an influx of approvals.

Dr. Voss on Phase I/II Trial Data of MEDI0680/Durvalumab Versus Nivolumab in mRCC

December 6th 2019

Martin H. Voss, MD, discusses results of a randomized phase I/II trial looking at the combination of MEDI0680 and durvalumab (Imfinzi) versus nivolumab (Opdivo) in metastatic renal cell carcinoma.

New Perioperative Strategies Emerge for High-Risk, Resectable RCC

December 4th 2019

The current management of metastatic renal cell carcinoma reflects the progress of medical oncology throughout the past several decades. The standard of care has evolved from cytokine-based therapies to targeted molecular therapies and immune checkpoint inhibitor–based strategies.

Dr. Beckermann on Sequencing Strategies in mRCC

December 4th 2019

Kathryn E. Beckermann, MD, PhD, instructor of medicine, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, discusses sequencing strategies in metastatic renal cell carcinoma (mRCC).

Dr. Davis on IMvigor130 Trial in Metastatic Urothelial Cancer

December 3rd 2019

Nancy B. Davis, MD, discusses the results of the phase III IMvigor130 trial in metastatic urothelial cancer.

Breadth of RCC Treatment Options Includes Novel Agents and Combo Strategies

December 2nd 2019

Kathryn E. Beckermann, MD, PhD, discusses the available single-agent and combination options for the treatment of patients with metastatic renal cell carcinoma.

FDA Label Change Takes a Bite Out of Prescriptions

November 26th 2019

Immunotherapy prescriptions for patients with metastatic bladder cancer declined rapidly after the FDA altered the indications of 2 drugs, suggesting that oncologists can keep pace with changes associated with the agency’s accelerated approval program.

Dr. Castle on Minimally Invasive Surgical Approaches in RCC

November 20th 2019

Erik P. Castle, MD, discusses minimally invasive surgical approaches in renal cell carcinoma.

Erdafitinib Tackles an Unmet Need in Urothelial Carcinoma

November 14th 2019

As the first targeted therapy in bladder cancer, erdafitinib (Balversa) expands the limited treatment options for the subset of patients with urothelial carcinoma.